Meet David S. Paik MD

Nuclear Medicine Specialist in Parsippany

Dr. David PaikDavid S. Paik is Board Certified by the American Board of Radiology. He received his BS in Chemistry from Virginia Commonwealth University in Richmond, VA. He then went to Virginia Commonwealth University School of Medicine in Richmond, VA where he received his MD.

 Dr. Paik completed a Transitional Medicine Internship at Georgetown University Hospital, Inova Fairfax Hospital in Washington DC, and Falls Church in Virginia. He also completed 4 years of a Diagnostic Radiology Residency at Yale-New Haven Medical Center in New Haven Connecticut.

 Dr. Paik has presented and published on a large variety of subjects, including oncology and nuclear medicine.

Call us at Memorial Radiology Associates Phone Number 973-503-5700 or Book Online to schedule an appointment with our practice.



 Kosaka N, Ogawa M, Paik DS, Paik CH, Choyke P, Kobayashi H. Semi-quantitative assessment of microdistribution of fluorescence-labeled monoclonal antibody in small peritoneal disseminations of ovarian cancer. Cancer Sci. 2010 Mar;101(3):820-5. Epub 2009 Oct 31.

 Maggio SC, Rosato RR, Kramer LB, Dai Y, Rahmani M, Paik DS, Czarnik AC, Payne SG, Spiegel S, Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res. 2004 Apr 1;64(7):2590-600.

 Kim MK, Jeong HJ, Kao CH, Yao Z, Paik DS, Pie JE, Kobayashi H, Waldmann TA, Carrasquillo JA, Paik, CH. Improved renal clearance and tumor targeting of 99mTc-labeled anti-Tac monoclonal antibody Fab by chemical modifications. Nucl Med Biol. 2002 Feb;29(2):139-46.

 Johnson LD, Willoughby CA, Burke SH, Paik DS, Jenkins KJ, Tombes RM. delta Ca(2+)/Calmodulin-dependent protein kinase II isozyme-specific induction of neurite outgrowth in P19 embryonal carcinoma cells. J Neurochem. 2000 Dec;75(6):2380-91.

 Kobayashi H, Le N, Kim IS, Kim MK, Pie JE, Drumm D, Paik DS, Waldmann TA, Paik CH, Carrasquillo JA. The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. Cancer Res. 1999 Jan 15;59(2):422-30.

 Kobayashi H, Le N, Kim IS, Kim MK, Drumm D, Paik DS, Waldmann TA, Paik CH, Carrasquillo JA. Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment. J Nucl Med. 1999 May;40(5):837-45.